**Technology Brief:** Biomarkers predicting response to immunosuppression in myelodysplastic syndromes

Docket Number: 07A056

| Summary | MDS (myelodysplastic syndromes) may be treated by immuno-suppressive therapies such as anti-thymocyte globulin.  
|        | Patient responses to these therapies is variable. Hence methods are needed to better predict responses to immuno-suppressive therapy.  
|        | A Moffitt researcher has discovered biomarkers for predicting response of MDS patients to therapy with anti-thymocyte globulin. |
| Features and Benefits | The method is based on T-cell surface markers that can be assayed by routine flow cytometry methods.  
|                    | The markers are well known and can be measured with standard reagents.  
|                    | Simple ratios of certain T-cell populations predict which patients will respond to therapy with anti-thymocyte globulin. |
| Stage of Development | Retrospective proof of concept. Clinical trials are under way. |
| Inventor | Dr. P. K. Eppling-Burnette |
|                    | US Patent Pending |

**Contact Information:**

**Haskell Adler PhD MBA**  
Senior Licensing Manager  
Email: haskell.adler@moffitt.org  
Telephone: 813-745-6596

**H. Lee Moffitt Cancer Center and Research Institute, Inc.**  
Office of Technology Management and Commercialization  
12902 Magnolia Drive MRC-TTO  
Tampa, FL 33612  
Website: [http://www.moffitt.org/OTMC](http://www.moffitt.org/OTMC)